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Abstract
Background Achieving adequate blood pressure (BP) con-
trol often requires more than one antihypertensive agent. The
purpose of this study was to determine whether a ﬁxed-dose
formulation of losartan (LOS) plus hydrochlorothiazide
(HCTZ) (LOS/HCTZ) is effective in achieving a greater BP
lowering in patients with uncontrolled hypertension.
Methods The study was a prospective, multicenter, obser-
vational trial exploring the antihypertensive effect of a single
tablet of LOS 50 mg/HCTZ 12.5 mg. A total of 228 patients
whose BP had previously been treated with more than one
antihypertensive agents without having achieved BP goal
below 130/80 mmHg enrolled in the study.
Results A signiﬁcant decrease in systolic and diastolic BP
was observed in both clinic and home measurement after
switching fromthe previous treatmenttoLOS/HCTZ.There
was a signiﬁcant decrease in both B-type natriuretic peptide
(BNP) and urinary albumin creatinine (Cr) excretion ratio
(ACR), especially in patients with elevated values. In con-
trast, there was a signiﬁcant increase in serum Cr concen-
tration in conjunction with a decrease in estimated
glomerular ﬁltration rate (eGFR). Overall serum uric acid
(UA) concentration increased, whereas in patients with
hyperuricemiatherewasasigniﬁcantreductioninthisvalue.
Conclusion Switching to LOS/HCTZ provides a greater
reduction in clinic and home BP in patients with uncon-
trolled hypertension. This combination therapy may lead to
cardio-, reno protection and improve UA metabolism.
Keywords Losartan  Hydrochlorothiazide 
Hypertension  BNP  Albuminuria
Introduction
AplethoraofevidencehasindicatedthatstrictBPreductionis
indispensable to improve patients’ prognosis, inadequate
control ofBPisthus leavingpatientsatriskofcardiovascular
disease, particularly in patients with chronic kidney disease
(CKD) and uncontrollable hypertension [1]. Despite the
increasing awareness of antihypertensive treatment, only a
small proportion of patients achieve the recommended target
goalsaroundtheworld[2–5].Forinstance,theBPgoalssetby
hypertension management guidelines in Japan are currently
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Similar low rates of hypertension control have been reported
worldwide[3,4].Thereasonfortheinadequacyofcontrolling
hypertension could at least in part be accounted for by phy-
sician’s insufﬁcient knowledge on how to prescribe appro-
priate antihypertensive agents.
Through reviewing the literature, Bakris et al. [6] have
suggested that in order to achieve lower BP of less than
130/80 mmHg, more than two drugs are needed in most
patients. Indeed, many guidelines for the management of
hypertension have recommended that combination of mul-
tipleantihypertensiveagentswithdifferentpharmacological
mode of action is more efﬁcacious than a single agent alone
[3]. In this context, the combination of an angiotensin II
receptor blocker (ARB) and hydrochlorothiazide (HCTZ)
has been widely recognized as a preferable prescription,
because combining ARB with HCTZ exerts a complemen-
tary pharmacological effect by suppressing renin angioten-
sinsystem(RAS)withtheformerandbodyﬂuidsystemwith
the latter, which provides a greater reduction in BP than
eitheragentalone.LOScombinedwiththesmalldoseHCTZ
as a ﬁxed dose single-tablet formulation, is one such option
thathasdemonstratedsubstantialantihypertensiveeffect[7].
LOS is unique in that it is the only ARB that has a uricosuric
effect that leads to a decreased serum uric acid (UA) levels.
This effect could be mediated by the inhibition of the urate
transporter URAT-1 in the renal tubules [8]. Owing to this
speciﬁc beneﬁt on UA metabolism, LOS has been known to
ameliorate diuretic-induced hyperuricemia [8, 9].
Despite substantial antihypertensive effect, thiazide
diuretics including HCTZ often induce adverse effects such
as hypokalemia, impaired glucose tolerance and an
increase in serum UA concentration. These side effects of
HCTZ could be minimized if prescribed in a lower dosage.
A ﬁxed-dose combination formula of LOS (50 mg; the
optimal dose) plus a low dose HCTZ (12.5 mg; a half of
the optimal dose) (LOS/HCTZ) is thus worth evaluating in
terms of BP lowering potency and avoiding side effects.
In the present study, we made an attempt to evaluate the
clinical beneﬁt of a single-tablet formulation of LOS/
HCTZ, by conducting a multicenter observational trial, the
Jikei Optimal Antihypertensive Treatment (JOINT) study
in uncontrolled hypertensive patients.
Methods
Study subjects
Eligible patients were men and women between 20 and
75 years of age with essential hypertension and those with
CKD with hypertension. Ethnic extraction of all partici-
pants was Japanese with all four biological grandparents
born in Japan and of Japanese descent. The inclusion cri-
teria were outpatients whose BP was more than
130/80 mmHg despite the antihypertensive agents pre-
scribed for more than 3 months prior to study entry. The
exclusion criteria were patients whose serum creatinine
(Cr) concentration exceeded 220 lmol/L (compatible with
CKD stage 5), those with liver dysfunction (deﬁned as an
elevation of aspartate aminotransferase/alanine amino-
transferase 3 times higher than the upper normal limit),
pregnant, expecting, or lactating women, CKD patients
with massive proteinuria of nephrotic range (deﬁned as a
daily protein excretion of 3 g/day or more), and patients
whose doctor in charge judged it inappropriate to enroll.
Study protocol
All institutions received prior ethics committee and or
institutional review board approval, and the trial was con-
ducted in accordance with the principles of Good Clinical
Practice and the ethical principles of the concurrent Decla-
ration of Helsinki which also protected the privacy of the
patients. All patients gave written informed consent before
study enrollment. The JOINT was a multicenter observa-
tional self-controlled study to evaluate the antihypertensive
effect of a ﬁxed-dose combination formulation of LOS/
HCTZ (Clinical trial Number by UMIN 000001950). The
study was conducted at 28 centers and clinics for the JOINT
study group (‘‘Appendix’’) in the vicinity of Tokyo, Japan.
Patients were previously treated with either one or more
antihypertensive agents on an outpatient basis. The proto-
col for the administration of LOS/HCTZ was the following.
If the patient was being treated with either ARB or calcium
channel blocker (CCB) alone or together, LOS/HCTZ was
substituted for either drug or the combination. If the patient
was being treated with three drugs including RAS inhibi-
tors, the RAS inhibitor was switched to LOS/HCTZ. In all
of the protocol patterns, LOS/HCTZ was administered
once a day in the morning.
Advices on life-style modiﬁcation plan were carried out
throughout the study. Namely, from the run-in and the
observation period, the patients were required to maintain a
daily salt intake of 6 g or less. A protein restriction of
0.6–0.8 g/kg/day was also required when the patient’s CCr
was below 30 mL/min/1.73 m
2. The other lifestyle modiﬁ-
cations included smoking cessation, weight reduction,
moderation in alcohol consumption, mild to moderate reg-
ular exercise, and reduction in saturated and total fat intake.
Endpoints
The primary endpoint was the change in clinic systolic and
diastolic BP after 6 months of treatment. Secondary end-
points included change in home BP, urinary albumin
270 Clin Exp Nephrol (2012) 16:269–278
123creatinine excretion ratio (ACR), B-type natriuretic peptide
(BNP) and serum UA concentration.
BP measurements and laboratory tests
The clinic BP was measured in a sitting position during a
morning visit (9–11 am) every 4 weeks. We followed all
AmericanHeartAssociationRecommendationspublishedin
1988 [8, 10] including using a 47 9 13 cm cuff and
24 9 13 cm bladder to avoid cuff hypertension. The cuff
was strictly positioned 2 cm above the antecubital crease to
obtain a similarly leveled complete compression of the
brachial artery. All BP values were expressed as the average
of two measurements obtained at the same time-point.
Patients were required to measure home BP in the
morning in a sitting position within 30 min after awakening
beforetakingmedicationsinafastingstate.Nighttimehome
BP measurement was also required to measure at any given
time between supper and bedtime with having patient’s
habitual drinking unrestricted. BP measuring devices
equipped with upper arm cuff were encouraged to use. The
averages of several measured values were used for analysis.
Laboratory tests carried out after 6 months of treatment
were BNP, serum Cr concentration, ACR, estimated-GFR
(eGFR), serum UA concentration, and others including
lipid proﬁles. The urinary albumin level was determined
from a spot urine sample using a turbidimetric immuno-
assay (SRL, Tokyo, Japan). Plasma BNP was measured
using high-sensitivity, noncompetitive radioimmunoassays
(Shiono-RIA BNP, Shionogi Inc, Osaka, Japan)
Statistical analyses
The paired student’s t test, Wilcoxon’s signed rank test,
and one-way analysis of variance (ANOVA) and Bonfer-
roni’s post hoc test were carried out with JMP 9.0 software.
The computer used for the analysis was a Dynabook
Satellite 2590X (Toshiba, Tokyo, Japan).
Dataare presentedasthemean ± standarddeviation(SD)
forcontinuousvariableswithnormaldistribution.Continuous
variableswithoutnormaldistributionarepresentedasmedian
and interquartile range (IQR) with 25 and 75 percentiles.
Because of their skewed distribution, logarithmic transfor-
mation of BNP and ACR values were performed as the geo-
metricmeanswith95%conﬁdenceintervals.APvalueofless
than 0.05 was considered statistically signiﬁcant.
Results
Prescription of antihypertensive agents
A total of 277 patients were registered in the JOINT study,
of whom 49 were excluded (33 were lost during follow-up,
7 had protocol violations, and 9 had inadequate data for
analyses). Consequently a total of 228 patients with clinical
index data were included in the analysis. The majority of
the patients (n = 142, 62%) had an eGFR more than
60 mL/min/1.73 m
2 (Table 1).
The baseline medications were monotherapy in 55%,
dual therapy in 32% and therapy with 3 or more drugs in
13%. The majority of patients were taking ARBs (72%) or
CCBs (54%), with only low numbers taking beta-blockers
(6%), alpha-blockers (6%), or angiotensin converting
enzyme inhibitors (ACE-I) (5%). At the beginning of the
study, almost half of the patients (48%) switched from
ARB to LOS/HCTZ, while 18% switched from CCB to
LOS/HCTZ, 15% switched from ARB ? CCB to LOS/
HCTZ, and 20% switched to the prescriptions in which one
of the pre-prescribed drugs was substituted by LOS/HCTZ.
Changes in clinic and home BP
Figure 1 shows the antihypertensive effect of LOS/HCTZ
on clinic BP. After 6 months of switching from the base-
line medications to LOS/HCTZ, signiﬁcant decreases in
clinic BP were observed in both systolic (145 ± 13 to
135 ± 15 mmHg) and diastolic BP (87 ± 9t o8 1 ± 9
mmHg, both comparisons P\0.001). The overall
achieving rate of BP goal of either systolic BP less than
130 mmHg or diastolic BP less than 80 mmHg was 53%
(120/228 cases).
Decreases in the clinic systolic and diastolic BP were
observed in all of the following 3 patterns (Fig. 2); patients
switched from ARB to LOS/HCTZ (145 ± 12/88 ± 8t o
134 ± 12/80 ± 10 mmHg, both systolic and diastolic,
P\0.001); from CCB to LOS/HCTZ (147 ± 11/87 ± 10
to 134 ± /80 ± 10 mmHg, both systolic and diastolic,
P\0.001); and from ARB ? CCB to LOS/HCTZ ? CCB
(140 ± 11/87 ± 11 to 131 ± 9/82 ± 9 mmHg, both sys-
tolic and diastolic, P\0.001).
Table 1 Patient baseline characteristics (n = 228)
Age (years) 60.3 ± 11.5
Gender (male/female) 158 (69%)/70 (31%)
BMI (kg/m
2) 25.3 ± 4.4
Diabetes (n) 35 (15%)
Dyslipidemia (n) 76 (33%)
Heart disease (n) 8 (4%)
CKD stage (n)
1 (eGFR C90) 23 (10%)
2 (60 B eGFR\90) 119 (52%)
3 (30 B eGFR\60) 70 (31%)
4 (15 B eGFR\30) 11 (5%)
BMI body mass index, eGFR estimated glomerular ﬁltration rate
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classiﬁed by BP response, the responders deﬁned as a
reduction in systolic BP of C10 mmHg, had a greater
systolic (responders, 150 ± 13 mmHg vs. non-responders,
140 ± 10 mmHg, P = 0.044) and diastolic BP (respond-
ers, 88 ± 9 mmHg vs. non-responders, 86 ± 10 mmHg,
P = 0.041) at the entry of the trial.
Figure 3 shows the results of home BP measurements.
Morning BP was signiﬁcantly decreased from 142 ± 12/
87 ± 11 mmHg at baseline to 130 ± 17/80 ± 11 mmHg
(both systolic and diastolic, P\0.001). Night time BP was
also decreased from 137 ± 12/86 ± 9 mmHg to
124 ± 10/78 ± 9 mmHg (both systolic and diastolic,
P\0.001). The signiﬁcant BP reduction was apparent
from month 1 and continued throughout the study period of
6 months.
Changes in laboratory tests
Table 2 shows changes in various parameters at the
beginning and end of the observation period. There was an
increase in serum Cr concentration (84.9 ± 34.5 to
89.3 ± 38.9 lmol/L, P\0.001) in conjunction with a
decrease in eGFR (from 65.6 ± 21.2 to 63.4 ± 20.7 mL/
min/1.73 m
2, P\0.001). Additionally, there was a sig-
niﬁcant decrease in serum sodium (Na) concentration
(from 141.5 ± 2.1 to 140.8 ± 2.7 mEq/L, P\0.001). No
changes were found in blood lipids and serum potassium
(K) concentration.
Figure 4 depicts changes in BNP after switching from
the original prescription to LOS/HCTZ ridden regimen.
The overall median BNP level signiﬁcantly decreased from
18.8 to 15.4 pg/dL (P\0.05). In patients whose BNP at
baseline was more than 18.4 pg/dL (above the normal
range, n = 96), the median level of BNP also decreased
from 34.4 to 25.4 pg/dL (P\0.01).
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Fig. 1 Effect of LOS/HCTZ on clinic BP (all patients). SBP systolic
blood pressure, DBP diastolic blood pressure, LOS/HCTZ losartan/
hydrochlorothiazide, ANOVA one-way analysis of variance
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Fig. 2 Effect of LOS/HCTZ on
clinic BP (various switching
patterns). SBP systolic blood
pressure, DBP diastolic blood
pressure, LOS/HCTZ losartan/
hydrochlorothiazide, CCB Ca
channel blockers, ANOVA one-
way analysis of variance
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Fig. 3 Effect of LOS/HCTZ on home BP (all patients). SBP systolic
blood pressure, DBP diastolic blood pressure, LOS/HCTZ losartan/
hydrochlorothiazide, ANOVA one-way analysis of variance
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123Figure 5 shows the BNP response as a function of BP
response. In 135 responders deﬁned as a reduction in sys-
tolic BP of C10 mmHg, the median BNP fell from 21.7 to
14.4 pg/dL (P\0.05), whereas there was no change in
BNP in 93 non-responders whose systolic BP reduction
was less than 10 mmHg.
Figure 6 shows changes in ACR. The overall median
value decreased from 21.7 to 13.9 mg/gCr (P\0.05). In
patients whose baseline ACR more than 30 mg/gCr (above
the abnormal range, n = 67), the median value decreased
from 108.0 to 52.0 mg/gCr (P\0.01).
Changes in ACR between BP responders deﬁned as a
reduction in systolic BP of C10 mmHg after 6 months and
non-responders (systolic BP reduction \10 mmHg) to
treatment with LOS/HCTZ were comparable, with a sig-
niﬁcant reduction in both groups (data not shown).
Figure 7 shows changes in serum UA concentration.
Although the ﬂuctuation remained within the normal range,
overall serum UA concentration increased (355 ± 93 to
367 ± 92 lmol/L, P\0.05). When patients were classi-
ﬁed into a high-UA group (UA C416 lmol//L) and a low-
UA group (UA \416 lmol/L), a signiﬁcant increase was
observed in the low-UA group (315 ± 65 to
333 ± 77 lmol/L, P\0.01). In contrast, in the high-UA
group there was a signiﬁcant decrease in UA value
(473 ± 47 to 454 ± 63 lmol/L, P\0.05).
Changes in BNP, ACR and serum UA levels were
analyzed in the presence and absence of CKD (deﬁned as
e-GRF B60 mL/min/1.73 m
2). The reduction in ACR
in the non-CKD group was greater than that in the
CKD group (CKD: -0.12 ± 0.31 mg/gCr vs. non-CKD:
-0.24 ± 0.36 mg/gCr, P = 0.044). No difference in the
other parameters was found between the two groups.
Changes in BNP and ACR were also analyzed in con-
junction with changes in clinic BP. A signiﬁcant associa-
tion was found between the reduction in systolic BP and
the decrease in BNP (r = 0.208, P = 0.004), and ACR
(r = 0.290, P\0.001). The reduction in diastolic BP was
correlated only with the decrease in ACR (r = 0.291,
P\0.001).
Table 2 Laboratory tests before and after the treatment with LOS/
HCTZ
Baseline 6 months P value
s-Cr (lmol/L) 84.9 ± 34.5 89.3 ± 38.9 \0.001
Na (mmol/L) 141.5 ± 2.1 140.8 ± 2.0 \0.001
K (mmol/L) 4.3 ± 0.6 4.3 ± 0.6 0.940
LDL-C (mmol/L) 3.0 ± 0.7 3.0 ± 0.7 0.356
HDL-C (mmol/L) 1.5 ± 0.4 1.5 ± 0.4 0.118
TG (mmol/L) 1.9 ± 1.5 1.9 ± 1.3 0.938
Hb (g/L) 139 ± 18 139 ± 17 0.903
Ht (%) 42.1 ± 4.5 41.8 ± 4.6 0.141
RBC (910
12/L) 4.49 ± 0.5 4.47 ± 0.51 0.428
WBC (910
9/L) 6.2 ± 1.7 6.3 ± 1.8 0.508
Platelets (910
9/L) 232 ± 55 233 ± 55 0.670
eGFR(mL/min/1.73 m
2) 65.6 ± 21.2 63.4 ± 20.7 \0.001
Laboratory tests before (baseline) and after (6 months) the treatment
with LOS/HCTZ
s-Cr serum creatinine concentration, Na serum sodium concentration,
K serum potassium concentration, LDL-C LDL cholesterol, HDL-C
HDL cholesterol, TG triglyceride, Hb hemoglobin, Ht hematocrit,
eGFR estimated glomerular ﬁltration rate
Median ± IQR
by Wilcoxon signed rank test
*: p <0.05, **: p < 0.01
15.4
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All patients (n=228)
Subgroup analysis
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Note: The upper normal limit of BNP is 18.4 pg/dL.  
(pg/dL) (pg/dL)
Fig. 4 Changes in BNP in
response to LOS/HCTZ. BNP
B-type natriuretic peptide, LOS/
HCTZ losartan/
hydrochlorothiazide
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123Discussion
BP lowering effect of LOS/HCTZ
Similar to the recommendations from hypertension guide-
line worldwide [1, 4, 11, 12], the guideline of Japanese
Society of Hypertension (JSH) recommends the use of
diuretics as ﬁrst-line antihypertensive treatment [5]. A
ﬁxed dose combination of LOS/HCTZ which contains
normal dose of LOS (50 mg) and a low dose HCTZ
(12.5 mg) has lately come into clinical practice. The
present study clearly demonstrated that switching to LOS/
HCTZ consistently led to a potent antihypertensive effect
regardless of the mode of BP (clinic or home, morning or
night: Figs. 1, 2), or the types of the pre-prescribed drugs
(switching patterns: Fig. 3). Similar results were reported
by Kita et al. [7] in a 1-year study of Japanese patients in
which switching from ARBs or ACE-Is to LOS/HCTZ was
carried out (The PALM-1 study). Their observation
showed that after the treatment with LOS/HCTZ, 50% of
patients fulﬁlled the targeted goals of the JSH guideline for
systolic BP and 79% for diastolic BP. The achieving rate of
130/80 mmHg in the present study (53%) coincides with
these results. A randomized controlled study reported by
14.8
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Median ± IQR
by Wilcoxon signed rank test
*: p < 0.05 
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15.9 15.9
0
10
20
30
40
50
0M 6M
(pg/dL) (pg/dL)
Fig. 5 Changes in BNP
classiﬁed by BP response.
Responders were deﬁned as
patients whose systolic BP
reduction was more than
10 mmHg. LOS/HCTZ losartan/
hydrochlorothiazide
Median ± IQR
by Wilcoxon signed rank test
*: p < 0.05, **: p < 0.01
(mg/gCr)
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Fig. 6 Changes in ACR in
response to LOS/HCTZ. LOS/
HCTZ losartan/
hydrochlorothiazide, ACR
albumin creatinine excretion
ratio
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123Ando et al. evaluated the effect of telmisartan, an ARB,
plus low dose HCTZ compared with an increased dose of
amlodipine, a CCB, when switched from amlodipine. The
Effect of lowering BP was more profound in the telmi-
sartan plus HCTZ group than in the increased dose of
amlodipine group (The ONEAST study) [13].
The potent antihypertensive effect of LOS/HCTZ may
partially be derived from the characteristics of the Japa-
nese, whose intake of salt is traditionally high with the
main sources including soy sauce, miso, salted ﬁsh, and salt
added at the table [14, 15]. Salt-sensitive hypertension is
associated with an impaired renal capacity to properly
excrete sodium and water, resulting in a therapy-resistant
hypertension. Of importance is that high salt suppresses the
RAS, thereby diminishing the action of RAS inhibitors.
Indeed, in 40–50% of the essential hypertensive popula-
tion, adrenal and renal vascular responses to AII do not
exhibit the expected changes predicted by changes in
sodium intake [15]. In contrast, diuretics potentiate the
RAS by contracting circulation volume, leading to an
effective BP reduction, especially if salt intake of patients
is high. The combination of an ARB and a diuretic is,
therefore, considered advantageous in terms of strict BP
control in salt sensitive patients with hypertension. Of note
is that the present study showed that the responders had
higher BP at entry, suggesting ‘‘the higher the BP, the
better the response’’ characteristic with the combination of
LOS/HCTZ in patients with uncontrolled hypertension.
Effect of LOS/HCTZ on renal function and electrolytes
Although the ﬂuctuations were kept within the normal
range, decrease in eGFR in conjunction with increased
serum Cr concentration is a matter for debate. It is apparent
that both are attributable to the use of diuretic. Substantial
evidences have demonstrated that diuretic reduces GFR.
For instance, studies exploring the effect of ARB/HCTZ
repeatedly showed a reduction in eGFR in association with
an increase in serum Cr concentration [7, 16, 17].
Decreased eGFR owing to the use of diuretics could be
explained by the contraction of circulating plasma volume.
Whether the decreased eGFR is a precipitating factor for
the preservation of residual renal function is unknown.
However, to date, a large body of reports has conﬁrmed
that diuretics are unequivocally efﬁcacious in preventing
major cardiovascular events, which include SHEP [18],
ALLHAT [19], ACCOMPLISH [20], EWPHE [21], HY-
VET [22] and ADVANCE [23]. Moreover, a large scale
PROBE trial exploring the effect of combination therapy
performed in Japan suggested that the diuretic-ridden reg-
imen was effective to prevent composite cardiovascular
events [24]. One can, therefore, speculate that both the
increased serum Cr concentration and the decreased eGFR
could have been the result of a transient volume contraction
due to the use of diuretic.
Although the change was subtle and entirely asymptom-
atic, the signiﬁcance of decrease in the serum Na concen-
tration may also be disputable. Adverse effect of
hyponatremia is a well-recognized complication of treat-
ment with thiazide that occurs predominantly in patients
older than 70 years [25]. Two elements are associates with
symptomatic hyponatremia. Such factors are diuretic at
higher dosage (HCTZ dose between 35 and 50 mg) and low
salt intake with a preexisting reduction in free water clear-
ance or a high ﬂuid intake [12]. Unless these two conditions
meet, serious hyponatremia is unlikely occur particularly if
patients are mobile. Uzu et al. [26] showed that treatment
with HCTZ 12.5 mg and LOS 50 mg did not induce signif-
icant reduction in serum Na concentration. The present
study, however, cast a caution that careful monitoring of
serum Na concentration is indispensable in the treatment
with HCTZ, even in a low prescribed dose of 12.5 mg.
200
300
400
500
600
0M 6M
200
300
400
500
600
0M 6M
high-UA (n=73)
low-UA   (n=155)
(µmol/L) (µmol/L)
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*
paired t test  *: p < 0.05  **: p < 0.01
All patients (n=228)
Subgroup analysis Fig. 7 Changes in UA in
response to LOS/HCTZ UA:
serum uric acid concentration.
High UA: patients whose serum
UA concentration C416 lmol//
L. Low-UA group patients
whose serum UA concentration
\416 lmol/L
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123With respect to serum K concentration, our study
showed that there was no change in this parameter. Com-
bining LOS with HCTZ exerts a beneﬁcial offsetting effect
in K metabolism, because the former increases serum K
concentration and the latter decreases, diminishing the risk
of either hyper-, or hypokalemia.
Effect of LOS/HCTZ on BNP and ACR
There was a substantial decrease in BNP, a marker for
cardiac hypertrophy (Fig. 4). Furthermore, the reduction in
BNP was obvious in patients with elevated BNP values and
in those who responded well to the therapy, suggesting that
the BNP lowering effect depends on BP reduction (Fig. 5).
Strict BP control, therefore, appears to be indispensable for
cardio-protection.
There was a substantial decrease in ACR, and the effect
was profound especially in patients with elevated ACR
(Fig. 6). The reno-protective effects of LOS have been
demonstrated in the RENAAL study in patients with type 2
diabetic nephropathy [27]. The risk of a doubling of the
serum Cr concentration, end-stage renal disease, or death
from any cause, was reduced by about 16–28% with LOS.
In addition, the LIFE study, demonstrating the superiority
of LOS over atenolol for reduction of CV morbidity and
mortality, was accompanied by the reduction in albumin-
uria [28–30]. The present study clearly conﬁrmed that
treatment with LOS/HCTZ is effective to improve
microalbuminuria.
Decreases in BNP and ACR may portend good clinical
outcomes for cardio- and reno-protection. However, longer
term follow up would be needed to prove such.
Effect of LOS/HCTZ on UA metabolism
Despite the potent antihypertensive effect, diuretics have
been less frequently used in clinical practice for fear of
their adverse effects, including increase in serum UA
concentration. In the present study, a subtle but signiﬁcant
increase in serum UA concentration was observed in
overall patients, although such changes still remained
within the normal range (Fig. 7). Of note is that when
patients were stratiﬁed into a high-UA group and a low-UA
group, signiﬁcant decrease was observed only in the for-
mer. The same results were noted in the study by Kita et al.
[7] who reported that while UA levels were kept within
normal ranges a signiﬁcant decrease in UA levels was
observed in patients with hyperuricemia (The PALM-1
study). A recent post hoc analysis also conﬁrmed that LOS
lowers serum UA levels compared with placebo in patients
with diabetic nephropathy [31]. The mechanisms by which
LOS/HCTZ reduces UA levels in patients with
hyperuricemia is largely attributable to uricosuric action of
LOS, which has been known to be mediated by the inhi-
bition of the UA transporter URAT-1 in the renal tubules
[8, 9]. In the high-UA group, the uricosuric action of LOS
might offset the hyperuricemic action of HCTZ, resulting
in a decreased UA level in the high-UA group.
Limitation of the present study
The present study has limitation. It is not a randomized
controlled study and no control group was used. Further
study in a randomized, controlled fashion will help to
strengthen the ﬁndings of this study.
In conclusion, a ﬁxed dose combination formula of LOS
plus HCTZ is efﬁcacious in achieving BP goal in patients
with uncontrolled hypertension. In addition, cardio-, reno-
protective effects may also be anticipated.
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